NCT04736589: Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: PI3K, Akt, mTOR
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 3
Drug Category: Serine-Threonine Kinase Inhibitor, Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 85 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with a history of pyrotinib and/or mTOR inhibitors (e.g. Afinitor/everolimus); Patients with symptomatic CNS metastases or evidence of leptomeningeal disease

Comments are closed.

Up ↑